Prostatype Genomics
2.15
SEK
+12.57 %
Less than 1K followers
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
+12.57%
-54.45%
-77.6%
-80.63%
-84.64%
-90.05%
-99.76%
-
-99.68%
Prostatype Genomics is active in medical technology. The company specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. The operations are found worldwide with the largest presence in the Nordic market.
Read moreMarket cap
14.7M SEK
Turnover
99K SEK
Revenue
200K
EBIT %
-20,425 %
P/E
-
Dividend yield-%
-
Financial calendar
22.5
2025
General meeting '25
23.7
2025
Interim report Q2'25
12.2
2026
Annual report '25
All
Press releases
ShowingAll content types
Prostatype Genomics AB resolves on a rights issue of units to fund completion of US validation study and Medicare approval process as well as ongoing commercialization activities in the US and Europe
Prostatype Genomics newsletter highlights positive U.S. study results and increasing clinical use in Italy
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools